

After Final,
Phase Enter
MS
9/10/04

AMENDMENTS TO THE CLAIMS:


Amend the claims as follows:

Claims 1-9 (Canceled).

10. (Currently Amended) A fusion polypeptide which comprises a human granulocyte colony stimulating factor polypeptide and c-mpl ligand polypeptide and has no mouse IL-3 activity as measured by inability to stimulate growth of Ba/F3 cells, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence in which the amino acid nos. 155 to 328 of the amino acid sequence shown in SEQ ID NO:1 is replaced by an amino acid sequence of SEQ ID NO:39 or by an amino acid sequence in which the amino acid nos. 155 to 328 of the amino acid sequence shown in SEQ ID NO:1 is replaced by an amino acid sequence of SEQ ID NO:46 having a set of substitutions selected from the group consisting of those of selected from an amino acid sequence represented in Table 1 and Table 2 a) to j) and l).

11. (Currently Amended) A fusion polypeptide which comprises a human granulocyte colony stimulating factor polypeptide and c-mpl ligand polypeptide and has no mouse IL-3 activity as measured by inability to stimulate growth of Ba/F3 cells, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence in which the amino acid nos. 155 to 328 of the amino acid sequence shown in SEQ ID NO:1 is replaced by an amino acid sequence of SEQ ID NO:39 or by an amino acid sequence in which the amino acid nos. 155 to 328 of the amino acid sequence

shown in SEQ ID NO:1 is replaced by an amino acid sequence of SEQ ID NO:46
having a set of substitutions selected from the group consisting of those of
~~selected from an amino acid sequence represented in Table 1 and Table 2 a) to~~
j) and l), and the human granulocyte colony stimulating factor polypeptide is
fused via a spacer peptide to the c-mpl ligand polypeptide.

9 12. (Currently Amended) The fusion polypeptide according to claim 1, 
wherein the polypeptide is selected from a polypeptide comprising the amino
acid sequence shown in SEQ ID NO:2 or SEQ ID NO:3, an amino acid sequence
in which the amino acid nos. 167 to 340 of the amino acid sequence shown in
SEQ ID NO:2 is replaced by an amino acid sequence of SEQ ID NO:39 or by an
amino acid sequence in which the amino acid nos. 167 to 340 of the amino acid
sequence shown in SEQ ID NO:2 is replaced by an amino acid sequence of
SEQ ID NO:46 having a set of substitutions selected from the group consisting of
those of selected from the amino acid sequences represented in Table 1 and
Table 2 a) to j) and l), and an amino acid sequence in which the amino acid nos.
171 to 344 of the amino acid sequence shown in SEQ ID NO: 3 is replaced by an
amino acid sequence of SEQ ID NO:39 or by an amino acid sequence in which
the amino acid nos. 171 to 344 of the amino acid sequence shown in SEQ ID
NO:3 is replaced by an amino acid sequence of SEQ ID NO:46 having a set of
substitutions selected from the group consisting of those of selected from the
~~amino acid sequences represented in Table 1 and Table 2 a) to j) and l).~~

2 13. (Previously Presented) The fusion polypeptide of claim 10¹ chemically modified with a polyalkylene glycol derivative.

3 14. (Previously Presented) The fusion polypeptide according to claim 13² wherein the polyalkylene glycol derivative is a polyethylene glycol derivative, a polypropylene glycol derivative or a polyoxyethylene-polyoxypropylene copolymer derivative.

4 15. (Previously Presented) A pharmaceutical composition for treating anemia comprising the fusion polypeptide of claim 10¹ in a pharmaceutically acceptable carrier, vehicle or auxiliary agent.

5 16. (Previously Presented) A method of treating anemia comprising administering to a subject in need of same an effective amount of the fusion polypeptide of claim 10¹.

6 17. (Previously Presented) A method of simultaneously amplifying platelets and neutrophils comprising administering to a subject in need of same an effective amount of the fusion polypeptide of claim 10¹.

7 18. (Currently Amended) A method of ~~controlling formation of~~
~~megakaryocyte colonies and neutrophil colonies and/or~~ controlling differentiation
or maturation of megakaryocyte precursors and neutrophil precursors comprising

YOKOI et al
Appl. No. 09/680,514
July 7, 2004

administering to a subject in need of same an effective amount of the fusion
polypeptide of claim 10.